Illumina and Mayo Clinic Form Bioinformatics Relationship to Advance Genetic Disorder Testing

Illumina, Inc. (NASDAQ: ILMN) today announced it has entered an agreement with Mayo Clinic to make advancements in next-generation sequencing technology with the intent to accelerate Mayo’s delivery of genetic and genomic expertise.
Together, the organizations plan to integrate existing services and
software tools and employ new, innovative solutions to improve Mayo
Clinic’s reporting workflows for researching inherited disease, enabling
Illumina to develop an informatics platform and knowledge base that can
improve and automate genomic interpretation.
As part of the agreement, Mayo Clinic will implement BaseSpace Clarity
LIMS in specific laboratories to provide testing of the tool. BaseSpace
Clarity LIMS is a system to provide comprehensive workflow tracking and
integration in laboratories. Mayo Clinic will also deploy and provide
feedback on its use of BaseSpace Sequence Hub, a cloud-based genomics
computing environment for data analysis and management, and BaseSpace
Variant Interpreter, a cloud-based interpretation and reporting platform
designed to decrease the time and effort required to assess biological
insight from genomic data. The software solutions will be piloted by
Mayo Clinic to annotate and interpret genetic variants with regard to
their potential role in the development and progression of diseases.
“Through this relationship, we will be able to generate large volumes of
genomic information, interrogate the data, and then compare it to what’s
known about those variants and those genetic aberrations in real time,
saving our geneticists time,” said William Morice, II, M.D., Ph.D.,
chair of Mayo’s Department of Laboratory Medicine and Pathology and
president of Mayo Medical Laboratories. “We are pleased to work with
Illumina and to leverage each other’s expertise in genetic sequencing
and analysis.”
“Mayo Clinic has been at the forefront of advanced medical research and
patient care for a long time,” said Sanjay Chikarmane, senior vice
president and general manager of Illumina Enterprise Informatics.
“BaseSpace Informatics Suite has the ability to provide a cloud-based
software solution that can manage, analyze and interpret data
automatically. We’re pleased that our offering will help Mayo Clinic
make sense of genomic data faster and more accurately.”
About BaseSpace Informatics Suite
BaseSpace Informatics Suite tools and solutions allow users to manage
and process data in one, secure unified system, from laboratory
information management and data storage, to analysis and interpretation.
This seamless integration between tools and solutions enables users to
save time by automating the process from the initial sample intake to
getting a report about genomic data, and provides high-quality, accurate
information with a fast turnaround time.
About Illumina, Inc.
Illumina is improving human health by unlocking the power of the genome.
Our focus on innovation has established us as the global leader in DNA
sequencing and array-based technologies, serving customers in the
research, clinical and applied markets. Our products are used for
applications in the life sciences, oncology, reproductive health,
agriculture, and other emerging segments. To learn more, visit www.illumina.com and
follow @illumina.
About Mayo
Clinic
Mayo Clinic is a nonprofit organization committed to clinical practice,
education, and research, providing expert, whole-person care to everyone
who needs healing. For more information, visit https://www.mayoclinic.org/about-mayo-clinic or https://newsnetwork.mayoclinic.org/.
About Mayo Medical Laboratories/Department of Laboratory Medicine and
Pathology
The Mayo
Clinic Department of Laboratory Medicine and Pathology and its
reference laboratory Mayo
Medical Laboratories provide advanced laboratory testing and
pathology services to support 5,000 health care organizations around the
world. Revenue from this testing is used to support medical education
and research at Mayo Clinic, a nonprofit worldwide leader in medical
care, research, and education for people from all walks of
life. Complemented by collaborations with diagnostic and biotechnology
companies, the department maintains a robust diagnostic test-development
program, launching more than 150 new tests each year.
Forward-Looking Statements
This release may contain forward-looking statements that involve risks
and uncertainties. Important factors that could cause actual results to
differ materially from those in any forward-looking statements are
detailed in our filings with the Securities and Exchange Commission,
including our most recent filings on Forms 10-K and 10-Q, or in
information disclosed in public conference calls, the date and time of
which are released beforehand. We do not intend to update any
forward-looking statements after the date of this release.